Skip to main content

Effect of orally administered Lactobacillus brevis HY7401 in a food allergy mouse model.

  • 2013-11
  • Journal of Microbiology and Biotechnology 23(11)
    • Jeongmin Lee
    • Jieun Bang
    • H. Woo

Abstract

We had found that orally administered Lactobacillus species were effective immune modulators in ovalbumin (OVA)-sensitized mice. To validate these findings, we investigated the effects of orally administered Lactobacillus brevis HY7401 in OVA-T cell receptor transgenic mice. This strain showed a tendency to induce Th1 cytokines and inhibit Th2 cytokines. All assayed isotypes of OVA-specific antibody were effectively reduced. Systemic anaphylaxis was also relatively reduced with the probiotic administration. These results reveal that L. brevis HY7401 might be useful to promote anti-allergic processes through oral administration.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus brevisReduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevisReduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevisReduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis HA-112Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis HA-112Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis LB01Reduced Allergic ResponsesBeneficial
Moderate
Lactobacillus brevis LB01Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis LB01Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis LB01Reduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis Lbr-35Induced Th1 CytokinesBeneficial
Moderate
Lactobacillus brevis Lbr-35Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis Lbr-35Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis Lbr-35Reduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced Allergic ResponsesBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis MAK11L82BReduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis SBC8803Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis SBC8803Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis SBC8803Reduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis SD-5214Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis SD-5214Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis SD-5214Reduced Th2 Cytokine LevelsBeneficial
Moderate
Lactobacillus brevis UALbr-02Reduced OVA-Specific AntibodiesBeneficial
Large
Lactobacillus brevis UALbr-02Reduced Systemic AnaphylaxisBeneficial
Moderate
Lactobacillus brevis VPro 18Increased Th1 Cytokine ProductionBeneficial
Moderate
Lactobacillus brevis VPro 18Reduced Th2 Cytokine ProductionBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.